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BEDITORIALational Institutes of Health Consensus Development
roject on Criteria for Clinical Trials in Chronic
raft-versus-Host Disease: Preface to the Series
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r“Miracles do not occur at random”
—C.D. Bowen
Chronic graft-versus-host disease (GVHD) des-
erately needs fresh attention. Current criteria for
iagnosis and staging were developed 25 years ago and
ere based on a small single-center patient series [1],
nd the current standard therapy evolved from the
rinciples developed in 1980s [2]. As a result of chang-
ng practices in allogeneic hematopoietic cell trans-
lantation (HCT) and improvement in survival after
CT, the number of patients with chronic GVHD is
ncreasing [3]. At the same time, chronic GVHD re-
eives little attention at national meetings, and there is
o Food and Drug Administration (FDA)–approved
edication for chronic GVHD. Clinical research seek-
ng to better understand chronic GVHD lags behind
ther innovations in HCT.
One of the main barriers to clinical research in
hronic GVHD is the absence of standardized criteria
or diagnosis, staging, and response criteria in this
isorder [4,5]. Several efforts have been made to ad-
ress this problem, including discussions at the Tan-
em BMT meetings, but no structure exists to sustain
hese efforts. The idea of a National Institutes of Health
NIH)–sponsored conference on chronic GVHD was
dvanced after a joint Johns Hopkins and National
ancer Institute (NCI) workshop that addressed this
ubject in early 2003. It was clear that the problem
eeded more effort than could be sustained by a single
r small group of investigators. Likewise, it was clear
hat the effort had to be supported by the broadest
ossible transplant constituency to avoid the develop-
ent of different sets of staging/response criteria that
as previously impeded progress in some other areas
f medicine.
The Chronic GVHDConsensus Project started as
joint initiative of the intramural and extramural
rograms of the NCI, National Heart, Lung and
lood Institute, National Institute of Allergy and In-
ectious Diseases, and NIH Director’s Ofﬁce and was
wiftly embraced by the Health Resources and Ser-
ices Administration and the Department of Defense A
B&MTaval Medical Research Center. The FDA was in-
olved early, because a major long-term goal of the
roject was the development of new therapies for
hronic GVHD. The ﬁrst planning meeting was held
n June 2004 at the NIH ofﬁces in Rockville, MD, and
ncluded approximately 30 participants representing
he HCT community, related specialty consultants,
nd government agencies. Six working groups were
harged with preparing the introductory list of ques-
ions for each topic: diagnosis and staging of chronic
VHD, histopathology, biomarkers, response crite-
ia, supportive care, and design of clinical trials. From
he beginning, these groups tried to include as many
takeholders as possible so that recommendations
ould truly represent consensus opinion.
The work started in July 2004 with frequent con-
erence calls of the larger working groups, the steering
ommittee, and the planning committee to prepare
raft documents for the second planning meeting,
hich was held in November 2004. Approximately
00 participants attended this meeting to prepare doc-
ments for the subsequent consensus meeting. The
rst public discussion of key recommendations in
hese draft documents took place at the February 2005
andem meeting in Keystone, CO, and the ensuing
pirited discourse reafﬁrmed the imperative of this
nitiative.
To ensure wide participation at the June 2005
onsensus Meeting, members of European Group for
lood and Marrow Transplantation, American Soci-
ty for Blood and Marrow Transplantation, Center
or International Blood and Marrow Transplant Re-
earch, industry representatives, NIH scientists, and
atient representatives were invited to attend. The
eeting motto “Chronic GVHD—The Next Fron-
ier in Transplantation Research” encapsulated the
ood and enthusiasm of the 250 participants. The
eeting was organized as a series of panel discussions
o present the working group reports and a series of
ectures focusing on issues critical for future research
irections in the ﬁeld. A 60-day public comment pe-
iod regarding the working group reports ended in
ugust 2005.
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Editorial
9In this issue of Biology of Blood and Marrow Trans-
lantation, the ﬁrst working group’s report, “Diagnosis
nd Staging,” is published. This article will be fol-
owed each month by others from the remaining 5
orking groups. Although these articles represent
urrent consensus opinion guided by available pub-
ished evidence, the recommendations are provisional
nd will need to be tested and validated in future
linical trials.
A follow-up meeting to revisit the recommenda-
ions after clinical application is planned for 2008. We
nvite all investigators to send information about chronic
VHD studies, protocols, and other relevant experi-
nce and to provide suggestions for reﬁnements. These
ontributions should help to create a robust agenda
or the follow-up meeting. Your comments can be sub-
itted via the American Society for Blood and Marrow
ransplantation chronic GVHD guidelines Web site
http://www.asbmt.org/cGvHD_Guidelines). Interested
nvestigators and sponsors seeking partnerships should
lso contact the NCI Technology Transfer Branch
Web site: http://ttb.nci.nih.gov; telephone: 301-496-
477).
What comes next? This project has sparked re-
ewed interest in chronic GVHD research. The rec-
mmendations that have emerged from this initiative
re being applied in several projects in the United
tates, Canada, Europe, and Latin America. The broad
articipation of scientists at all levels in this effort has
ngaged a whole new generation of investigators. If
rogress is to be made in treatment of chronic GVHD,
oung investigators must perceive the ﬁeld as inter-
sting, exciting, and challenging at a basic and clinical
evel. Despite its obvious value, enthusiasm is not
ufﬁcient to carry us forward. Substantial effort must
e directed toward establishing new partnerships fo-
used on development of therapies for treatment of
hronic GVHD. In August 2005, the NIH conducted
44survey among investigators to identify the most
ritical directions for future chronic GVHD research,
nd the suggestions have been received. Finally, the
ew chronic GVHD recommendations were discussed
n a highly collaborative and scientiﬁc atmosphere at a
ecent FDA Oncology Coordinating Committee meet-
ng in July 2005. At that meeting, Stephanie Lee ﬁn-
shed her presentation by saying, “Tougher nuts have
een cracked.” This is now certainly true. We hope
hat you will ﬁnd the chronic GVHD articles in this
ssue and subsequent issues to be helpful in your work.
ongratulations go to all participants who gave so
enerously of their time and effort and to all those
ho in their hearts share the excitement of curing
ife-threatening diseases with the use of allogeneic
CT. The rewards go exclusively to our patients.
teven Pavletic, MD1
eorgia Vogelsang, MD2
National Cancer Institute
ethesda, Maryland
Johns Hopkins University School of Medicine
altimore, Maryland
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